Edition:
United States

Citius Pharmaceuticals Inc (CTXR.OQ)

CTXR.OQ on NASDAQ Stock Exchange Capital Market

3.60USD
22 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.60
Open
$3.74
Day's High
$3.74
Day's Low
$3.46
Volume
6,083
Avg. Vol
22,201
52-wk High
$5.46
52-wk Low
$0.34

Chart for

About

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortiso... (more)

Overall

Beta: --
Market Cap(Mil.): $30.32
Shares Outstanding(Mil.): 8.42
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.22 16.52
EPS (TTM): -- -- --
ROI: -- 14.09 36.19
ROE: -- 15.56 17.38

BRIEF-Citius Announces $6 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

Dec 18 2017

BRIEF-Citius Pharmaceuticals Says On Nov 27, Board Appointed Jaime Bartushak As CFO And Principal Financial Officer Of Co

* CITIUS PHARMACEUTICALS INC - ‍ON NOV 27, , BOARD APPOINTED JAIME BARTUSHAK AS CFO AND PRINCIPAL FINANCIAL OFFICER OF COMPANY, EFFECTIVE NOV. 27, 2017​ Source text: (http://bit.ly/2iwTNyZ) Further company coverage:

Dec 01 2017

BRIEF-Citius Pharmaceuticals files for mixed shelf offering of up to $50 mln - SEC filing‍​

* Citius Pharmaceuticals Inc - files for mixed shelf offering of up to $50 million - SEC filing‍​ Source text: (http://bit.ly/2zKcjdY) Further company coverage:

Nov 09 2017

BRIEF-Citius pharmaceuticals receives "fast track" designation by FDA for mino-lok™ investigational trial

* Citius Pharmaceuticals, Inc. Receives "fast track" designation by FDA for mino-lok™ investigational trial Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Oct 31 2017

BRIEF-Citius Pharmaceuticals provides phase 3 update on Mino-Lok clinical trial following FDA meeting

* Citius Pharmaceuticals, Inc provides phase 3 update on Mino-Lok™ clinical trial following FDA meeting

Sep 05 2017

Earnings vs. Estimates